Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Sairah Ahmed, Avyakta Kallam, Matthew Frigault, Bradley D. Hunter, Sagar S. Patel, David Bernasconi, Soyoung Kim, Tracy Krimmel, Fei Fei Liu, Debasmita Roy, Marcelo C. Pasquini, Jennifer L. Crombie

Blood (2024) 144 (Supplement 1): 472.

https://doi.org/10.1182/blood-2024-199702

Published: 2024

Journal Articles

Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Blood (2024) 144 (Supplement 1): 2134.1.

https://doi.org/10.1182/blood-2024-207952

Published: 2024

Journal Articles

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Blood (2024) 144 (Supplement 1): 694.

https://doi.org/10.1182/blood-2024-205917

Published: 2024

Journal Articles

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Arpita Gandhi, Rasmus T. Hoeg, Sagar S. Patel, Edmund K. Waller, Jeremy M. Pantin, Caspian H. Oliai, J. Scott McClellan, Anna Pavlova, Irene Agodoa, Nathaniel B. Fernhoff, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2023-188994

Published: 2023

Journal Articles

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Caspian H. Oliai, Jeremy M. Pantin, Rasmus T. Hoeg, Lori S. Muffly, Sagar S. Patel, Arpita Gandhi, Robert Lowsky, Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, J. Scott McClellan, Mehrdad Abedi, Robert S. Negrin, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 230.

https://doi.org/10.1182/blood-2023-186749

Published: 2023

Journal Articles

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Blood (2023) 142 (Supplement 1): 104.

https://doi.org/10.1182/blood-2023-180242

Published: 2023

Journal Articles

CAR-T Therapy in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Real World Outcomes Based on Tumor Biology

Luke Brinkman, Charlotte B Wagner, Jian Ying, Martina Fraga, Bernard L. Marini, Gianni Bruno Scappaticci, Jonathan Ptachcinski, Sagar S. Patel

Blood (2022) 140 (Supplement 1): 9546–9547.

https://doi.org/10.1182/blood-2022-170317

Published: 2022

Journal Articles

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Blood (2022) 140 (Supplement 1): 654–656.

https://doi.org/10.1182/blood-2022-165654

Published: 2022

Journal Articles

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Sagar S. Patel, MD, Kwang Woo Ahn, PhD, Manoj Khanal, BS, MS, Caitrin Fretham, MPH, Celalettin Ustun, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Shin Mineishi, MD, Bipin N. Savani, MD, Mohamed Sorror, MD MSc, Edward A. Stadtmauer, MD FACP, Brent Logan, PhD, Marcelo C. Pasquini, MDMS, Saurabh Chhabra, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140503

Published: 2020

Journal Articles

Comparative Effectiveness of Busulfan/Cyclophosphamide Versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Sagar S. Patel, MD, Lisa Rybicki, MS, Arden Emrick, Victoria Winslow, RN, Jamie Starn, RN, Jamie Elberson, RN, Brittany Hodgeman, RN, Brad Pohlman, MD, Brian J. Bolwell, MD, Aaron T. Gerds, MD MS, Betty K. Hamilton, MD, Rabi Hanna, MD, Matt Kalaycio, MD, Navneet S. Majhail, MD MS, Ronald Sobecks, MD

Blood (2018) 132 (Supplement 1): 3365.

https://doi.org/10.1182/blood-2018-99-113871

Published: 2018

Journal Articles

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Blood (2018) 132 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2018-99-110814

Published: 2018

Journal Articles

Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 4603.

https://doi.org/10.1182/blood-2018-99-111890

Published: 2018

Journal Articles

Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 2075.

https://doi.org/10.1182/blood-2018-99-112745

Published: 2018

Journal Articles

Implementation of an Electronic Medical Record Tool for Early Detection of Deep Vein Thrombosis in the Ambulatory Oncology Setting: The Cleveland Clinic Experience

Girish Kunapareddy, MD, Benjamin Switzer, DO, MHSA, MS, Madison Conces, MD, Pramod Pinnamaneni, MD, Bhumika J. Patel, MD, Sagar S. Patel, MD, Alicia Redden, Dana E. Angelini, MD, Keith McCrae, MD, Brad Pohlman, MD, Alok A. Khorana, MD

Blood (2017) 130 (Supplement 1): 3361.

https://doi.org/10.1182/blood.V130.Suppl_1.3361.3361

Published: 2017

Journal Articles

Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 532.

https://doi.org/10.1182/blood.V130.Suppl_1.532.532

Published: 2017

Journal Articles

Incidence, Treatment Patterns, and Outcomes of Histiocytic Disorders in the United States: A Forty-Year Population Study

Sagar S. Patel, MD, Girish Kunapareddy, MD, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Anjali S. Advani, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2017) 130 (Supplement 1): 2266.

https://doi.org/10.1182/blood.V130.Suppl_1.2266.2266

Published: 2017

Journal Articles

Influence of MHC Class I Chain-Related Gene Α (MICA) Polymorphisms on Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation

Sagar S. Patel, MD, Lisa Rybicki, MS, Melissa A. Yurch, Dawn Thomas, Robert M. Dean, MD, Hien D. Liu, MD, Deepa Jagadeesh, MDMPH, Aaron T. Gerds, MDMS, Brian T. Hill, MD PhD, Rabi Hanna, MD, Betty K. Hamilton, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Brian J. Bolwell, MD, Aiwen Zhang, PhD, Navneet S. Majhail, MD MS, Medhat Askar, MD PhD, Ronald Sobecks, MD

Blood (2017) 130 (Supplement 1): 748.

https://doi.org/10.1182/blood.V130.Suppl_1.748.748

Published: 2017

Journal Articles

Evolution in Myeloid Neoplasms Clonal Architecture Post Allogeneic Hematopoietic Cell Transplantation

Blood (2017) 130 (Supplement 1): 1682.

https://doi.org/10.1182/blood.V130.Suppl_1.1682.1682

Published: 2017

Journal Articles

Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy

Sagar S. Patel, MD, Tomas Radivoyevitch, PhD, Aaron T. Gerds, MD MS, Navneet S. Majhail, MD MS, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD

Blood (2016) 128 (22): 2786.

https://doi.org/10.1182/blood.V128.22.2786.2786

Published: 2016

Journal Articles

Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT)

Sagar S. Patel, MD, Lisa Rybicki, MS, Donna Abounader, BBA, CCRP, Brian J. Bolwell, MD, Robert Dean, MD, Hien K. Liu, MD, Aaron T. Gerds, MD MS, Rabi Hanna, MD, Brian T. Hill, MD PhD, Deepa Jagadeesh, MD MPH, Matt Kalaycio, MD, Brad Pohlman, MD, Ronald Sobecks, MD, Navneet S. Majhail, MD MS, Betty K. Hamilton, MD

Blood (2016) 128 (22): 4666.

https://doi.org/10.1182/blood.V128.22.4666.4666

Published: 2016

NARROW

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

CAR-T Therapy in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Real World Outcomes Based on Tumor Biology

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Comparative Effectiveness of Busulfan/Cyclophosphamide Versus Busulfan/Fludarabine Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia

Implementation of an Electronic Medical Record Tool for Early Detection of Deep Vein Thrombosis in the Ambulatory Oncology Setting: The Cleveland Clinic Experience

Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies

Incidence, Treatment Patterns, and Outcomes of Histiocytic Disorders in the United States: A Forty-Year Population Study

Influence of MHC Class I Chain-Related Gene Α (MICA) Polymorphisms on Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation

Evolution in Myeloid Neoplasms Clonal Architecture Post Allogeneic Hematopoietic Cell Transplantation

Forty-Year Analysis of Randomized Clinical Trials in Patients with Acute Myeloid Leukemia Treated with Remission Induction Chemotherapy

Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only